85753-12-4

Basic information

• Product Name: N-benzyl-L-alanine tert-butyl ester
• Synonyms: N-benzyl-L-alanine tert-butyl ester
• CAS NO: 85753-12-4
• Molecular Weight: 235.326
• Mol File: 85753-12-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: N-benzyl-L-alanine tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-benzyl-L-alanine tert-butyl ester(85753-12-4)
• EPA Substance Registry System: N-benzyl-L-alanine tert-butyl ester(85753-12-4)

Safety Data

• Hazardous Substances Data: 85753-12-4(Hazardous Substances Data)

Upstream product

• 21691-50-9 Ala-OtBu 
• 13404-22-3 tert-butyl L-alaninate hydrochloride 
• 100-39-0 benzyl bromide 
• 100-52-7 benzaldehyde 

Downstream Products

• 344765-16-8 N-benzyl-N-chloroacetyl-L-Ala-O^tBu 
• 256477-48-2 N-benzyl-N-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-L-alanine tert-butyl ester 
• 7585-47-9 N-benzyl-(S)-alanine 

Relevant articles and documents

Structure-Activity Relationship Studies of Hydantoin-Cored Ligands for Smoothened Receptor

An underside binding site was recently identified in the transmembrane domain of smoothened receptor (SMO). Herein, we report efforts in the exploration of new insights into the interactions between the ligand and SMO. The hydantoin core in the middle of the parent compound was found to be highly conservative in chirality, ring size, and substituents. On each benzene at two ends, a plethora of variations, particularly halogen substitutions, were introduced and investigated. Analysis of the structure-activity relationship revealed miscellaneous halogen effects. The ligands with double halogen substituents exhibit remarkably enhanced potency, providing promising candidates that potentially overcome the common drug resistance and useful heavy-atom labeled chemical tools for co-crystallization studies of SMO.

Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin

The dynorphin (Dyn) A analogue zyklophin ([N-benzyl-Tyr1-cyclo(d-Asp5,Dap8)]dynorphin A(1-11)NH2) is a kappa opioid receptor (KOR)-selective antagonist in vitro, is active in vivo, and antagonizes KOR in the CNS

Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines

1-Isoquinolinylguanidines were previously disclosed as potent and selective inhibitors of urokinase-type plasminogen activator (uPA). Further investigation of this template has revealed that incorporation of a 7-sulfonamide group furnishes a new series of potent and highly selective uPA inhibitors. Potency and selectivity can be achieved with sulfonamides derived from a variety of amines and is further enhanced by the incorporation of sulfonamides derived from amino acids. The binding mode of these 1-isoquinolinylguanidines has been investigated by X-ray cocrystallization studies. uPA inhibitor 26 was selected for further evaluation based on its excellent enzyme potency (Ki 10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin). In vitro, compound 26 is able to inhibit exogenous uPA in human chronic wound fluid (IC50 = 0.89 μM). In vivo, in a porcine acute excisional wound model, following topical delivery, compound 26 is able to penetrate into pig wounds and inhibit exogenous uPA activity with no adverse effect on wound healing parameters. On the basis of this profile, compound 26 (UK-371,804) was selected as a candidate for further preclinical evaluation for the treatment of chronic dermal ulcers.